BioSpace News Archive

Aims to raise USD 10 million via token sale; forecasts USD 12 million in revenue within three years of launch through an Asian-centric phased launch approach with subscriptions to consumers and organisations

Leaders in gut health testing, Brisbane-based Microba, has backed sufferers of Inflammatory Bowel Disease (IBD) through a donation of $3000 worth of sales during May to support IBD organisation Crohn’s and Colitis Australia (CCA) and the launch of a program targeted at finding relief for those with IBD in June.

TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, announces today the appointment of Maryellen Papelian as senior director of customer delivery.

Company to install 17 in-store drug disposal units in select Longs Drugs locations in July to provide community access to safe disposal of unwanted medications

In the latest collaboration in a series to advocate for genomics research, Integrated DNA Technologies (IDT) is teaming up with 3CR Bioscience (3CR) to widen access to quality custom solutions for genotyping screening.

Antibodies.com, a digital marketplace that enables life scientists to purchase critical research reagents at cost-effective prices from the primary manufacturers, today announced that is has raised £400,000 in pre-seed financing.

Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease.

Ora®, Inc. (“Ora”) announced that it and its affiliate, OIG LLC (“OIG”), have entered into a partnership with InFocus Capital Partners LLC. Ora is committed to supporting early, mid, and late stage companies in strategy, nonclinical, regulatory, and clinical development.

The Microbiome Therapeutics Innovation Group (MTIG) announced today the appointment of a new chairman, Ken Blount, Ph.D., Chief Scientific Officer of Rebiotix, Inc. Dr. Blount replaces Tom DesRosier, Esq., Chief Legal Officer of Seres Therapeutics, who served as MTIG Chairman since the coalition’s inception in 2018

Asieris MediTech Co, Ltd, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, and Photocure ASA, The Bladder Cancer Company, announced that they have entered into a License Agreement for world-wide development and commercialization of Cevira® for the treatment of HPV induced cervical precancerous lesions.